CN101257904A - Pde4或pde3/4抑制剂和组胺受体拮抗剂的药物组合物 - Google Patents

Pde4或pde3/4抑制剂和组胺受体拮抗剂的药物组合物 Download PDF

Info

Publication number
CN101257904A
CN101257904A CNA038053349A CN03805334A CN101257904A CN 101257904 A CN101257904 A CN 101257904A CN A038053349 A CNA038053349 A CN A038053349A CN 03805334 A CN03805334 A CN 03805334A CN 101257904 A CN101257904 A CN 101257904A
Authority
CN
China
Prior art keywords
inn
tetrahydrochysene
phthalazines
bases
ketone
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA038053349A
Other languages
English (en)
Chinese (zh)
Inventor
R·伯伊姆
D·邦舒
C·维马
S·-L·沃林
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda GmbH
Original Assignee
Nycomed GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nycomed GmbH filed Critical Nycomed GmbH
Publication of CN101257904A publication Critical patent/CN101257904A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4425—Pyridinium derivatives, e.g. pralidoxime, pyridostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Otolaryngology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
CNA038053349A 2002-03-06 2003-02-25 Pde4或pde3/4抑制剂和组胺受体拮抗剂的药物组合物 Pending CN101257904A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP02004987.0 2002-03-06
EP02004987 2002-03-06

Publications (1)

Publication Number Publication Date
CN101257904A true CN101257904A (zh) 2008-09-03

Family

ID=27771841

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA038053349A Pending CN101257904A (zh) 2002-03-06 2003-02-25 Pde4或pde3/4抑制剂和组胺受体拮抗剂的药物组合物

Country Status (31)

Country Link
US (1) US20050112069A1 (enExample)
EP (2) EP1849468B1 (enExample)
JP (1) JP5150034B2 (enExample)
KR (1) KR20040095255A (enExample)
CN (1) CN101257904A (enExample)
AR (1) AR038858A1 (enExample)
AT (1) ATE369134T1 (enExample)
AU (1) AU2003212268B2 (enExample)
BR (1) BR0308220A (enExample)
CA (1) CA2478612C (enExample)
CO (1) CO5611148A2 (enExample)
CY (2) CY1106927T1 (enExample)
DE (1) DE60315426T2 (enExample)
DK (2) DK1482938T3 (enExample)
EA (2) EA010886B1 (enExample)
ES (2) ES2400670T3 (enExample)
HR (1) HRP20040909B1 (enExample)
IL (1) IL163336A (enExample)
IS (2) IS2536B (enExample)
MX (1) MXPA04008460A (enExample)
NO (1) NO335254B1 (enExample)
NZ (1) NZ535611A (enExample)
PL (1) PL211574B1 (enExample)
PT (2) PT1482938E (enExample)
RS (1) RS51018B (enExample)
SG (1) SG160197A1 (enExample)
SI (2) SI1849468T1 (enExample)
TW (1) TWI347845B (enExample)
UA (1) UA80117C2 (enExample)
WO (1) WO2003074055A1 (enExample)
ZA (1) ZA200407104B (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106604747A (zh) * 2014-08-26 2017-04-26 基础应用医学研究基金会 用于治疗和预防伴随认知缺陷或缺损的神经障碍以及神经变性疾病的产品
CN109956947A (zh) * 2017-12-25 2019-07-02 江苏恒瑞医药股份有限公司 一种cns抑制剂的新晶型、制备方法及用途

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009514969A (ja) * 2005-11-09 2009-04-09 コンビナトアールエックス インコーポレーティッド 医学的状態を治療するための方法、組成物、およびキット
DE602007005167D1 (de) * 2006-12-20 2010-04-15 Glaxo Group Ltd 4-benzyl-1(2h)-phthalazinone als h1-rezeptor-antagonisten
KR20100014565A (ko) * 2007-04-11 2010-02-10 알콘 리서치, 리미티드 알레르기성 비염 및 알레르기성 결막염을 치료하기 위한 ｔｎｆａ의 억제제 및 항히스타민의 용도
US20090182035A1 (en) * 2007-04-11 2009-07-16 Alcon Research, Ltd. Use of a combination of olopatadine and cilomilast to treat non-infectious rhinitis and allergic conjunctivitis
US8877816B2 (en) 2007-11-21 2014-11-04 Decode Genetics Ehf 4-(or 5-) substituted catechol derivatives
KR20090061972A (ko) * 2007-12-12 2009-06-17 한미약품 주식회사 베포타스틴 ｐ-톨루엔술폰산염의 결정형, 이의 제조방법 및이를 포함하는 약학 조성물
AU2012215606B2 (en) 2011-02-07 2016-12-22 Scipharm Sarl Novel composition for the treatment of cystic fibrosis
KR102226833B1 (ko) * 2013-06-28 2021-03-12 한미약품 주식회사 레보세티리진 및 몬테루카스트를 포함하는 안정성이 개선된 복합 과립 제형
AU2015330490B2 (en) 2014-10-09 2018-08-09 Guangdong Raynovent Biotech Co., Ltd. Hydroxyl purine compounds and applications thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2847693A1 (de) * 1978-11-03 1980-05-22 Hoechst Ag Verfahren zur herstellung von pyrimido-(6,1-a)-isochinolin-2-onen
AU650953B2 (en) 1991-03-21 1994-07-07 Novartis Ag Inhaler
US5712298A (en) * 1993-07-02 1998-01-27 Byk Gulden Lomberg Chemische Fabrik Gmbh Fluoroalkoxy-substituted benzamides and their use as cyclic nucleotide phosphodiesterase inhibitors
US5900421A (en) * 1997-02-11 1999-05-04 Sepracor Inc. Methods and compositions for treating allergic asthma and dermatitis using descarboethoxyloratadine
US5990147A (en) * 1997-11-07 1999-11-23 Schering Corporation H3 receptor ligands of the phenyl-alkyl-imidazoles type
BR9804993A (pt) * 1998-11-10 2000-06-06 Panacea Biotec Ltd Composição antialérgica e antiinflamatória
US6174878B1 (en) * 1999-08-31 2001-01-16 Alcon Laboratories, Inc. Topical use of kappa opioid agonists to treat otic pain
CN1146562C (zh) * 1999-10-25 2004-04-21 奥坦纳医药公司 作为pde4抑制剂的四氢噻喃2,3-二氮杂萘酮类衍生物
US7585847B2 (en) * 2000-02-03 2009-09-08 Coley Pharmaceutical Group, Inc. Immunostimulatory nucleic acids for the treatment of asthma and allergy
GB0115181D0 (en) * 2001-06-20 2001-08-15 Glaxo Group Ltd Novel use

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106604747A (zh) * 2014-08-26 2017-04-26 基础应用医学研究基金会 用于治疗和预防伴随认知缺陷或缺损的神经障碍以及神经变性疾病的产品
CN109956947A (zh) * 2017-12-25 2019-07-02 江苏恒瑞医药股份有限公司 一种cns抑制剂的新晶型、制备方法及用途

Also Published As

Publication number Publication date
AU2003212268A1 (en) 2003-09-16
IS7438A (is) 2004-09-03
JP5150034B2 (ja) 2013-02-20
SI1849468T1 (sl) 2013-03-29
NZ535611A (en) 2006-03-31
US20050112069A1 (en) 2005-05-26
DK1482938T3 (da) 2007-12-03
CY1106927T1 (el) 2012-09-26
SI1482938T1 (sl) 2007-12-31
WO2003074055A1 (en) 2003-09-12
EA007903B1 (ru) 2007-02-27
EA200401137A1 (ru) 2005-04-28
UA80117C2 (uk) 2007-08-27
CY1113894T1 (el) 2016-07-27
ES2400670T3 (es) 2013-04-11
TWI347845B (en) 2011-09-01
ATE369134T1 (de) 2007-08-15
EP1849468A2 (en) 2007-10-31
DE60315426T2 (de) 2008-07-03
EP1482938B1 (en) 2007-08-08
IS8760A (is) 2008-09-04
TW200306855A (en) 2003-12-01
SG160197A1 (en) 2010-04-29
CA2478612A1 (en) 2003-09-12
ES2291618T3 (es) 2008-03-01
EP1482938A1 (en) 2004-12-08
ZA200407104B (en) 2006-12-27
PT1849468E (pt) 2013-02-27
NO20044230L (no) 2004-12-06
PL211574B1 (pl) 2012-05-31
HRP20040909B1 (en) 2012-11-30
AU2003212268B2 (en) 2008-09-11
RS78004A (sr) 2006-12-15
DK1849468T3 (da) 2013-02-04
CO5611148A2 (es) 2006-02-28
KR20040095255A (ko) 2004-11-12
HK1071308A1 (en) 2005-07-15
CA2478612C (en) 2013-12-10
DE60315426D1 (de) 2007-09-20
NO335254B1 (no) 2014-10-27
PL371056A1 (en) 2005-06-13
BR0308220A (pt) 2005-01-04
PT1482938E (pt) 2007-11-15
IS2536B (is) 2009-08-15
JP2005524666A (ja) 2005-08-18
IL163336A (en) 2009-02-11
MXPA04008460A (es) 2004-12-06
HRP20040909A2 (en) 2005-08-31
AR038858A1 (es) 2005-01-26
RS51018B (sr) 2010-10-31
EP1849468B1 (en) 2012-12-05
EA200601592A1 (ru) 2006-12-29
EP1849468A3 (en) 2007-11-07
EA010886B1 (ru) 2008-12-30

Similar Documents

Publication Publication Date Title
TWI674264B (zh) ６，７－二氫吡唑并［１，５－ａ］吡－４（５Ｈ）－酮化合物及其作為ＭＧＬＵＲ２受體之負異位調節劑之用途
JP2012526737A (ja) １，２，３−トリアゾロ［４，３−ａ］ピリジン誘導体ならびに神経障害および精神障害の治療または予防のためのその使用
CN101257904A (zh) Pde4或pde3/4抑制剂和组胺受体拮抗剂的药物组合物
US20040006135A1 (en) Combination treatment for depression and anxiety
AU2003273396B2 (en) The use of the combination of ciclesonide and antihistamines for the treatment of allergic rhinitis
JPH08193033A (ja) 脳血管障害に伴う精神症候治療剤
JP2002338497A (ja) 抑うつ及び不安のための併合療法
TW202523323A (zh) 用於治療慢性心臟衰竭的吡唑並〔３，４－ｄ〕嘧啶酮化合物
TW200848041A (en) A medicament for treating schizophrenia comprising cilostazol
US20040001895A1 (en) Combination treatment for depression and anxiety
CN101573121A (zh) 毒蕈碱受体调节剂
JP2003146879A (ja) 精神分裂病治療及び／又は予防薬
HK1071308B (en) Pharmaceutical composition of a pde4 or a pde3/4 inhibitor and a histamine receptor antagonist
JP2003146973A (ja) うつ病、うつ状態又は不安障害の治療及び／又は予防薬
HK1080744A (en) The use of the combination of ciclesonide and antihistamines for the treatment of allergic ehinitis

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Open date: 20080903